Clinical practice guidelines and real-world practice for hepatocellular carcinoma in Taiwan: Bridging the gap

Taiwan’s NHI program accounts for the majority of health care expenditures in the country, and its policy has significant impacts on real-world practice for HCC by influencing the availability and accessibility of diagnostic tools and treatments. Analyzing the realworld practice data may be valuable...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and molecular hepatology 2023-04, Vol.29 (2), p.349-351
Main Author: Wang, Shen-Yung
Format: Article
Language:English
Subjects:
Biomarkers
Cancer therapies
Carcinoma, Hepatocellular - diagnosis
Carcinoma, Hepatocellular - pathology
Carcinoma, Hepatocellular - therapy
Chemoembolization
Clinical medicine
Clinical practice guidelines
Gastroenterology
Hepatitis
hepatocellular carcinoma
Hepatology
Humans
Kinases
Liver cancer
Liver diseases
Liver Neoplasms - diagnosis
Liver Neoplasms - pathology
Liver Neoplasms - therapy
Magnetic resonance imaging
National health insurance
Patients
Surveillance
systemic therapy
Taiwan
Tomography
Ultrasonic imaging
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Taiwan’s NHI program accounts for the majority of health care expenditures in the country, and its policy has significant impacts on real-world practice for HCC by influencing the availability and accessibility of diagnostic tools and treatments. Analyzing the realworld practice data may be valuable for evaluation of treatment and outcomes of HCC, which may facilitate NHI approval and help the development of practice consensus. Abbreviations AFP, alpha fetoprotein; CEUS, contrast-enhanced ultrasound; CT, computed tomography; GEST, Gastroenterological Society of Taiwan; HCC, hepatocellular carcinoma; ICI, immune checkpoint inhibitors; MRI, magnetic resonance imaging; NHI, National Health Insurance; PIVKA-II, protein induced by vitamin K absence or antagonist II; TACE, trans-arterial chemoembolization; TLCA, Taiwan Liver Cancer Association 1.
ISSN:2287-2728
2287-285X
DOI:10.3350/cmh.2023.0082